PacBio, Cantor Fitzgerald Amend Deal to Offer up to $30M in Stock | GenomeWeb

NEW YORK (GenomeWeb) – Pacific Biosciences said on Tuesday that it has amended an agreement with Cantor Fitzgerald to offer up to $30 million of its common stock from time to time. 

The agreement amends a deal that PacBio and Cantor Fitzgerald reached in October to sell up to $30 million of the next-generation sequencing firm's common stock. The amended agreement is for the sale of an additional $30 million, PacBio said in a document filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.